BRAF and neoplasm: Triple combination therapy with a BRAF inhibitor, a MEK inhibitor and pmel-1 adoptive cell transfer immunotherapy has been shown to increase T-cell infiltration into tumours and improve cytotoxicity in a murine model [49].